Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib + Gemcitabine in Advanced Cancer and Pancreatic Cancer
NCT00862524Phase 2Completed
- Sponsor
- Array BioPharma
- Start
- Mar 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of varlitinib in solid tumor and pancreatic cancer (PC), sponsored by Array BioPharma. Primary endpoints: Maximum Tolerated Dose, Safety Profile (Adverse Events, Labs, ECGs) and 2 more. Started Mar 2009; status: completed.
02
Drugs
varlitinib
03
Conditions
solid tumorpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00862524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862524.